pharmaphorum November 5, 2024
Novo Nordisk has partnered with Ascendis Pharma on less frequently dosed drugs for obesity and other metabolic diseases, starting with a once-monthly GLP-1 receptor agonist.
The Danish pharma group is pledging $285 million in upfront and milestone payments for the lead GLP-1 asset in the partnership, with another $77.5 million apiece on offer for any additional candidates it decides to take forward through development.
At the heart of the agreement is an exclusive worldwide license to Copenhagen-based Ascendis’ TransCon technology platform, which involves adding linker and carrier molecules to turn established medicines into prodrugs with improved delivery characteristics. The prodrugs eventually dissociate to release the active ingredient in a controlled manner, according to Ascendis.
The company has already demonstrated the...
Today's Sponsors
Today's Sponsor